TDMS Study 88004-06 Pathology Tables
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
FINAL #1 MICE
Facility: Battelle Northwest
Chemical CAS #: 1321-74-0
Lock Date: 06/17/02
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 11 12 8 7
Natural Death 6 3 3 1
Accidently Killed 1
Survivors
Terminal Sacrifice 33 35 38 42
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (41) (36) (41)
Intestine Large, Colon (48) (50) (50) (50)
Intestine Large, Cecum (47) (49) (48) (50)
Intestine Small, Duodenum (46) (48) (48) (49)
Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Jejunum (46) (48) (48) (49)
Carcinoma 2 (4%)
Liver (49) (50) (50) (50)
Hepatocellular Carcinoma 3 (6%) 4 (8%) 3 (6%) 2 (4%)
Hepatocellular Carcinoma, Multiple 2 (4%)
Hepatocellular Adenoma 12 (24%) 4 (8%) 5 (10%) 4 (8%)
Hepatocellular Adenoma, Multiple 5 (10%) 3 (6%) 1 (2%) 1 (2%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (17) (16) (4) (5)
Pancreas (48) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (50)
Stomach, Forestomach (50) (50) (50) (50)
Stomach, Glandular (49) (50) (49) (49)
Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Adrenal Medulla (49) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Pheochromocytoma Malignant 2 (4%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (48) (49) (49) (50)
Carcinoma 1 (2%)
Pituitary Gland (47) (50) (49) (45)
Histiocytic Sarcoma 1 (2%)
Pars Distalis, Adenoma 8 (17%) 8 (16%) 1 (2%) 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (49) (50) (48)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (48) (50) (49) (49)
Cystadenoma 3 (6%) 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%)
Uterus (49) (50) (50) (49)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Fibroma 1 (2%)
Histiocytic Sarcoma 2 (4%)
Polyp Stromal 1 (2%) 3 (6%) 2 (4%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (50) (50)
Hemangiosarcoma 2 (4%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node (9) (3) (5) (2)
Renal, Carcinoma, Metastatic, Mammary Gland 1 (50%)
Lymph Node, Bronchial (43) (46) (39) (39)
Lymph Node, Mandibular (41) (45) (44) (41)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (49) (50) (49) (49)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mediastinal (44) (44) (38) (38)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Carcinoma, Metastatic, Mammary Gland 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (2%)
Spleen (49) (50) (49) (49)
Hemangiosarcoma 3 (6%)
Histiocytic Sarcoma 1 (2%)
Thymus (49) (47) (46) (44)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (49) (50) (49)
Carcinoma 2 (4%)
Carcinoma, Multiple 1 (2%)
Skin (50) (50) (50) (50)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Neural Crest Tumor 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteoma 1 (2%)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (1)
Carcinoma, Metastatic, Mammary Gland 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Meningioma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (48) (50) (50) (49)
Lung (50) (50) (50) (49)
Alveolar/Bronchiolar Adenoma 4 (8%) 9 (18%) 4 (8%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 3 (6%) 4 (8%) 5 (10%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 2 (4%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 2 (4%) 1 (2%)
Nose (50) (50) (50) (49)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Olfactory Epithelium, Neuroblastoma 1 (2%)
Trachea (49) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50) (50) (50) (49)
Harderian Gland (50) (50) (50) (50)
Adenoma 4 (8%) 1 (2%) 4 (8%) 5 (10%)
Carcinoma 2 (4%) 4 (8%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (49) (50) (50) (49)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymphoma Malignant 11 (22%) 10 (20%) 5 (10%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 40 26 26
Total Primary Neoplasms 68 66 37 41
Total Animals with Benign Neoplasms 28 21 14 19
Total Benign Neoplasms 42 30 17 25
Total Animals with Malignant Neoplasms 22 29 19 13
Total Malignant Neoplasms 25 36 20 16
Total Animals with Metastatic Neoplasms 4 5 2 2
Total Metastatic Neoplasm 4 6 2 12
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 7 6 5 4
Natural Death 2 6 3 3
Survivors
Terminal Sacrifice 41 38 42 43
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (34) (42) (45)
Adenoma 1 (2%)
Intestine Large, Rectum (48) (45) (46) (47)
Leiomyosarcoma 1 (2%)
Intestine Large, Cecum (48) (46) (47) (48)
Carcinoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Leiomyoma 1 (2%)
Polyp Adenomatous 1 (2%)
Intestine Small, Duodenum (48) (45) (47) (47)
Carcinoma 1 (2%)
Intestine Small, Jejunum (48) (45) (47) (47)
Carcinoma 3 (6%) 4 (9%)
Intestine Small, Ileum (48) (45) (47) (47)
Carcinoma 1 (2%)
Liver (50) (50) (50) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 3 (6%) 1 (2%)
Hepatoblastoma 2 (4%)
Hepatocellular Carcinoma 12 (24%) 9 (18%) 7 (14%) 7 (14%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (4%) 2 (4%) 3 (6%)
Hepatocellular Adenoma 10 (20%) 12 (24%) 10 (20%) 11 (22%)
Hepatocellular Adenoma, Multiple 12 (24%) 5 (10%) 2 (4%) 1 (2%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Oral Mucosa (1)
Pharyngeal, Squamous Cell Carcinoma 1 (100%)
Pancreas (49) (48) (50) (50)
Page 8
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Carcinoma 1 (2%)
Stomach, Forestomach (49) (50) (49) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Stomach, Glandular (48) (48) (47) (49)
Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hemangiosarcoma 2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (49) (50) (50)
Adenoma 1 (2%)
Capsule, Adenoma 3 (6%)
Adrenal Medulla (49) (49) (50) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 2 (4%)
Islets, Pancreatic (49) (48) (50) (50)
Adenoma 1 (2%)
Thyroid Gland (49) (49) (50) (50)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Testes (50) (50) (50) (50)
Hemangioma 1 (2%)
Interstitial Cell, Adenoma 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (48) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (2) (1)
Iliac, Leiomyosarcoma, Metastatic, Intestine
Large, Rectum 1 (50%)
Pancreatic, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (50%)
Lymph Node, Bronchial (35) (34) (33) (37)
Cholangiocarcinoma, Metastatic, Liver 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (39) (27) (35) (38)
Lymph Node, Mesenteric (44) (46) (47) (50)
Carcinoma, Metastatic, Pancreas 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Lymph Node, Mediastinal (37) (38) (33) (29)
Carcinoma, Metastatic, Pancreas 1 (3%)
Carcinoma, Metastatic, Intestine Small,
Duodenum 1 (3%)
Cholangiocarcinoma, Metastatic, Liver 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (3%)
Sarcoma, Metastatic, Skin 1 (3%)
Spleen (49) (48) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Page 10
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Forestomach 1 (2%)
Thymus (44) (41) (43) (44)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrous Histiocytoma 2 (4%) 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2)
Cholangiocarcinoma, Metastatic, Liver 1 (50%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (49) (49) (49) (49)
Alveolar/Bronchiolar Adenoma 10 (20%) 5 (10%) 6 (12%) 13 (27%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 4 (8%) 2 (4%) 8 (16%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibroma 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 5 (10%) 3 (6%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic, Bone
Marrow 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Bronchus, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (49) (50) (50)
Adenoma 5 (10%) 3 (6%) 6 (12%) 7 (14%)
Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 88004-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC DIVINYLBENZENE Date: 08/14/03
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:01:09
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 100 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 38 29 41
Total Primary Neoplasms 90 60 44 67
Total Animals with Benign Neoplasms 35 24 21 27
Total Benign Neoplasms 49 34 25 40
Total Animals with Malignant Neoplasms 26 21 14 23
Total Malignant Neoplasms 41 26 19 27
Total Animals with Metastatic Neoplasms 9 10 4 3
Total Metastatic Neoplasm 14 23 7 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------